197 related articles for article (PubMed ID: 11059569)
1. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences.
Köstler WJ; Brodowicz T; Hejna M; Wiltschke C; Zielinski CC
Cancer Detect Prev; 2000; 24(4):376-403. PubMed ID: 11059569
[TBL] [Abstract][Full Text] [Related]
2. [Minimal residual disease in solid cancer. Prognostic value and therapeutic consequences].
Allgayer H; Heiss MM
Fortschr Med Orig; 2001; 119(1):1-4. PubMed ID: 11935652
[TBL] [Abstract][Full Text] [Related]
3. Detection of micrometastatic disease in bone marrow: is it ready for prime time?
Janni W; Rack B; Lindemann K; Harbeck N
Oncologist; 2005 Aug; 10(7):480-92. PubMed ID: 16079315
[TBL] [Abstract][Full Text] [Related]
4. Detection and treatment of minimal residual disease in high-risk neuroblastoma.
Reynolds CP
Pediatr Transplant; 2004 Jun; 8 Suppl 5():56-66. PubMed ID: 15125707
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual marrow disease: detection and significance of isolated tumour cells in bone marrow.
Iorgulescu DG; Kiroff GK
ANZ J Surg; 2001 Jun; 71(6):365-76. PubMed ID: 11409023
[TBL] [Abstract][Full Text] [Related]
6. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
Ghossein RA; Rosai J
Cancer; 1996 Jul; 78(1):10-6. PubMed ID: 8646704
[TBL] [Abstract][Full Text] [Related]
7. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
[TBL] [Abstract][Full Text] [Related]
8. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
[TBL] [Abstract][Full Text] [Related]
10. [Micrometastases in pediatric oncology].
Bernard F; Aerts I; Margueritte G; Astruc J
Bull Cancer; 2001 Jun; 88(6):577-80. PubMed ID: 11459704
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and significance of minimal residual disease in patients with colorectal carcinoma].
von Knebel Doeberitz M; Koch M; Weitz J; Herfarth C
Zentralbl Chir; 2000; 125 Suppl 1():15-9. PubMed ID: 10929641
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
14. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases.
Toren A; Rechavi G; Nagler A
Stem Cells; 1996 May; 14(3):300-11. PubMed ID: 8724696
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
17. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fluorescent in situ hybridization (FISH) and the polymerase chain reaction (PCR) for detection of residual neuroblastoma cells.
Eckschlager T; McClain K
Neoplasma; 1996; 43(5):301-3. PubMed ID: 8996548
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
